Developer docs
API playgroundTry for free, no card

Search company profiles

SmartCardia

Full company profile

uuid0000yxz

Namestring
SmartCardia
Legal namestring
SmartCardia SA
Websiteurl
smartcardia.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

SmartCardia SA is a Lausanne, Switzerland-based medical technology company founded in 2013 that has developed a cable-free, waterproof 7-lead ECG patch paired with a cloud-based SaaS platform for continuous cardiac and remote patient monitoring. The patch supports 7- or 14-day continuous monitoring with full-disclosure signal transmission (100% of ECG data, not just events) to a cloud platform where SmartNeuralNet, the company's proprietary machine learning engine trained on millions of cardiologist-annotated ECG segments, performs automated arrhythmia detection, predictive patient deterioration alerts, and clinician-facing reporting. A single patch serves multiple service types — Mobile Cardiac Telemetry, Holter, Extended Holter, and Event Monitoring — with a remote 48-hour service-switch capability (Switch 48h) that avoids patient revisits, and a reusable sensor with low-cost disposable patches that lowers per-patient cost.

The company derives revenue from three streams: hardware sales of the reusable sensor and disposable patches, recurring SaaS subscriptions for the cloud analytics and reporting platform, and (in the US) professional diagnostic services billed through insurance via its wholly-owned subsidiary SmartCardia, Inc. (formerly Cardiomedix, Inc., a CMS-enrolled, Joint Commission-accredited IDTF acquired in December 2024). It sells primarily through enterprise field sales targeting hospitals, cardiac centers, and cardiology practices, with regional sales directors covering Europe, the UK, India/Gulf, and the US, and a US VP of Sales leading the post-acquisition commercial push. Regulatory assets include FDA clearance for 14-day continuous monitoring (Sept 2023) and for Mobile Outpatient Cardiac Telemetry (Nov 2024), CE Class IIa approval in Europe, and ISO 13485 and ISO 27001 certifications. The company is led by co-founders Srinivasan Murali (CEO) and Francisco Rincón (CTO), with Dr. Jag Singh (Harvard Medical School, former Mass General Cardiology Clinical Director) as Principal Advisor, and reports 100+ hospital customers, millions of monitored patient hours, and 10+ clinical studies underpinning its positioning, including the SMART-TEL study demonstrating a false-alarm rate of 5 vs 21 (P=.002) versus conventional telemetry.

SmartCardia is venture-backed (approximately $14M Series B in 2023 and a $7.5M Series A in 2018, plus early-stage Venture Kick support and 2024 MedTech Innovator selection) and operates from Lausanne with a US headquarters in Des Plaines, Illinois, and an India office in Mumbai, serving healthcare providers across the cardiac monitoring, electrophysiology, and remote patient monitoring value chain.

Short descriptiontext

SmartCardia builds a 7-lead wireless ECG patch and AI-powered cloud platform for continuous cardiac and remote patient monitoring, serving hospitals, cardiology practices, and RPM providers globally with FDA-cleared, CE-marked hardware, SaaS analytics, and US diagnostic services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLausanne, Switzerland
HQ citystring
Lausanne
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable ECG devices, cardiac monitoring solutions, remote patient monitoring, medical telemetry services, arrhythmia detection technology
Industry5 codes
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Cardiac Monitoring Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Hardware Sales
TypeHardware Sales
Description

Sale of 7-lead ECG patches (reusable sensors and disposable components) to hospitals and healthcare providers. The reusable sensor design with low-cost disposable patches supports recurring revenue from consumables.

smartcardia.com
2Cloud SaaS Platform
TypeSubscription Recurring
Description

Cloud-based arrhythmia detection, analysis, and reporting platform provided as SaaS to clinicians and healthcare systems. Powers real-time monitoring and automated analysis with SmartNeuralNet AI technology.

smartcardia.com
3Diagnostic Services (US)
TypeProfessional Services
Description

US diagnostic services through SmartCardia Inc. (formerly Cardiomedix), an accredited Independent Diagnostic Testing Facility (IDTF). Provides complete cardiac monitoring pathway including MCT and Holter monitoring services, billed through insurance.

smartcardia.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

SmartCardia manufactures a 7-lead wireless ECG patch and operates a cloud-based SaaS platform (SmartNeuralNet) for AI-powered cardiac arrhythmia detection and remote patient monitoring. The patch is cable-free, waterproof, and supports 7/14 days of continuous monitoring, transmitting 100% of ECG data and vitals (respiration, SpO2, activity) to the cloud in near real time. In the US, the company also operates an accredited Independent Diagnostic Testing Facility (IDTF) to deliver end-to-end cardiac monitoring services.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • False alarms significantly reduced: 5 vs 21 (CCMS) in SMART-TEL clinical study (P = .002)
+3 more records
Product and service2 records
1SmartCardia 7L Patch with Cloud Platform
CategoryCardiac Monitoring Devices
Description

Cable-free, waterproof wearable 7-lead ECG patch with companion SmartNeuralNet cloud SaaS platform for continuous 7/14-day cardiac and remote patient monitoring. Provides real-time full-disclosure ECG transmission, AI-driven arrhythmia detection, and clinical reporting for hospitals, cardiologists, and electrophysiologists. Single patch serves MCT, Holter, Extended Holter, and Event Monitoring services.

2US Cardiac Diagnostic Monitoring Services (IDTF)
CategoryCardiac Diagnostic Services
Description

Outsourced cardiac diagnostic monitoring services (MCT, Holter, Extended Holter, Event Monitoring) delivered through SmartCardia Inc., a wholly-owned US subsidiary operating as a CMS-enrolled IDTF with Joint Commission accreditation. Billed through in-network coverage with major US insurance providers.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1Cardiomedix, Inc. (acquired and renamed SmartCardia, Inc.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-12-18
Description

SmartCardia completed acquisition of Cardiomedix, Inc., a US Independent Diagnostic Testing Facility (IDTF). The acquisition closes the loop on SmartCardia's US offering, combining its FDA-cleared 7-Lead ECG Patch and AI-driven cloud platform with an accredited US diagnostic facility. Cardiomedix operates under SmartCardia brand as wholly-owned US subsidiary with CMS IDTF enrollment and Joint Commission accreditation, enabling end-to-end cardiac monitoring services in the US market.

smartcardia.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic is a global cardiac device leader with LINQ implantable loop recorders and broader cardiac diagnostics portfolio. Competes at the high-acuity end of cardiac monitoring and adjacent to SmartCardia's patch-based Holter/MCT offerings.

TypeDirect peer
Description

iRhythm's Zio is the market-leading wearable ECG patch for ambulatory cardiac monitoring. Direct competitor in 14-day continuous ECG monitoring with AI-driven arrhythmia detection, serving the same cardiology and hospital customer base.

TypeBroad incumbent
Description

GE HealthCare provides hospital telemetry systems, ECG carts, and patient monitoring infrastructure. Competes with SmartCardia in the inpatient telemetry use case and increasingly in wireless/remote monitoring through MUSE and other digital tools.

TypeEmerging player
Description

Heartbeam is a smaller public competitor developing 3D ECG signal capture technology for ambulatory cardiac monitoring with AI-driven analysis. Comparable in targeting outpatient telemetry with a differentiated hardware platform.

TypeDirect peer
Description

AliveCor's KardiaMobile and KardiaCloud offer consumer-and-professional ECG monitoring with AI-driven arrhythmia detection. Overlaps with SmartCardia in ECG signal capture and cloud-based analysis, though more skewed toward consumer/ambulatory use cases.

TypeDirect peer
Description

Boston Scientific acquired Preventice (BodyGuardian) in 2022, a direct competitor offering remote cardiac monitoring patches and services (MCT, Event, Holter). Competes head-to-head with SmartCardia in hospital and IDTF channels.

TypeBroad incumbent
Description

Philips acquired BioTelemetry in 2021, one of the largest US remote cardiac monitoring service providers (MCOT, Holter, Event). Competes with SmartCardia's IDTF channel and offers a broader portfolio including hospital telemetry and sleep diagnostics.

8VitalConnect
TypeDirect peer
Description

VitalConnect provides wearable biosensor patches (Vista) for continuous vital sign and cardiac monitoring in both hospital and remote patient monitoring settings. Direct competitor in patch-based multi-vital monitoring with cloud analytics.

TypeDirect peer
Description

Baxter acquired Bardy Diagnostics (CAM patch), a single-lead ECG patch focused on ambulatory monitoring. Competes in the same cardiac monitoring patch category with comparable workflow and reimbursement models.

TypeEmerging player
Description

Eko offers AI-powered digital stethoscopes and ECG sensing with cloud analytics. Comparable in cloud-based cardiac AI interpretation and clinician workflow, though primarily device-form-factor different.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SmartCardia

Cardiac Monitoring Devicessmartcardia.com

SmartCardia builds a 7-lead wireless ECG patch and AI-powered cloud platform for continuous cardiac and remote patient monitoring, serving hospitals, cardiology practices, and RPM providers globally with FDA-cleared, CE-marked hardware, SaaS analytics, and US diagnostic services.

What SmartCardia does

SmartCardia SA is a Lausanne, Switzerland-based medical technology company founded in 2013 that has developed a cable-free, waterproof 7-lead ECG patch paired with a cloud-based SaaS platform for continuous cardiac and remote patient monitoring. The patch supports 7- or 14-day continuous monitoring with full-disclosure signal transmission (100% of ECG data, not just events) to a cloud platform where SmartNeuralNet, the company's proprietary machine learning engine trained on millions of cardiologist-annotated ECG segments, performs automated arrhythmia detection, predictive patient deterioration alerts, and clinician-facing reporting. A single patch serves multiple service types — Mobile Cardiac Telemetry, Holter, Extended Holter, and Event Monitoring — with a remote 48-hour service-switch capability (Switch 48h) that avoids patient revisits, and a reusable sensor with low-cost disposable patches that lowers per-patient cost.

The company derives revenue from three streams: hardware sales of the reusable sensor and disposable patches, recurring SaaS subscriptions for the cloud analytics and reporting platform, and (in the US) professional diagnostic services billed through insurance via its wholly-owned subsidiary SmartCardia, Inc. (formerly Cardiomedix, Inc., a CMS-enrolled, Joint Commission-accredited IDTF acquired in December 2024). It sells primarily through enterprise field sales targeting hospitals, cardiac centers, and cardiology practices, with regional sales directors covering Europe, the UK, India/Gulf, and the US, and a US VP of Sales leading the post-acquisition commercial push. Regulatory assets include FDA clearance for 14-day continuous monitoring (Sept 2023) and for Mobile Outpatient Cardiac Telemetry (Nov 2024), CE Class IIa approval in Europe, and ISO 13485 and ISO 27001 certifications. The company is led by co-founders Srinivasan Murali (CEO) and Francisco Rincón (CTO), with Dr. Jag Singh (Harvard Medical School, former Mass General Cardiology Clinical Director) as Principal Advisor, and reports 100+ hospital customers, millions of monitored patient hours, and 10+ clinical studies underpinning its positioning, including the SMART-TEL study demonstrating a false-alarm rate of 5 vs 21 (P=.002) versus conventional telemetry.

SmartCardia is venture-backed (approximately $14M Series B in 2023 and a $7.5M Series A in 2018, plus early-stage Venture Kick support and 2024 MedTech Innovator selection) and operates from Lausanne with a US headquarters in Des Plaines, Illinois, and an India office in Mumbai, serving healthcare providers across the cardiac monitoring, electrophysiology, and remote patient monitoring value chain.

SmartCardia firmographics

Firmographics
Name
SmartCardia
Legal name
SmartCardia SA
Website
https://smartcardia.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
51–100 employees
Short description
SmartCardia builds a 7-lead wireless ECG patch and AI-powered cloud platform for continuous cardiac and remote patient monitoring, serving hospitals, cardiology practices, and RPM providers globally with FDA-cleared, CE-marked hardware, SaaS analytics, and US diagnostic services.
Ownership category
akta.pro rank

SmartCardia industry classification

Industry
Product category
Cardiac Monitoring Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHACAB
Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAPAI
Clinical-Grade Vital Signs Monitoring (ECG, SpO2, BP, Temp, Respiration)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLACAPAK
Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)
Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring
SECONDARYHLALAFAA
Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)
Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

Keywords

  • Wearable ECG devices
  • Cardiac monitoring solutions
  • Remote patient monitoring
  • Medical telemetry services
  • Arrhythmia detection technology

Where SmartCardia is headquartered

Location

Headquarters

HQ city
Lausanne
HQ country
Switzerland
HQ region
Europe

Offices3 records

Markets served

SmartCardia business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Hardware Sales: Sale of 7-lead ECG patches (reusable sensors and disposable components) to hospitals and healthcare providers. The reusable sensor design with low-cost disposable patches supports recurring revenue from consumables.
  2. Cloud SaaS Platform: Cloud-based arrhythmia detection, analysis, and reporting platform provided as SaaS to clinicians and healthcare systems. Powers real-time monitoring and automated analysis with SmartNeuralNet AI technology.
  3. Diagnostic Services (US): US diagnostic services through SmartCardia Inc. (formerly Cardiomedix), an accredited Independent Diagnostic Testing Facility (IDTF). Provides complete cardiac monitoring pathway including MCT and Holter monitoring services, billed through insurance.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

SmartCardia product offering

Product offering

Core offering

SmartCardia manufactures a 7-lead wireless ECG patch and operates a cloud-based SaaS platform (SmartNeuralNet) for AI-powered cardiac arrhythmia detection and remote patient monitoring. The patch is cable-free, waterproof, and supports 7/14 days of continuous monitoring, transmitting 100% of ECG data and vitals (respiration, SpO2, activity) to the cloud in near real time. In the US, the company also operates an accredited Independent Diagnostic Testing Facility (IDTF) to deliver end-to-end cardiac monitoring services.

Differentiator

Problem solved

Functional benefit

Products and services

  • SmartCardia 7L Patch with Cloud Platform Cable-free, waterproof wearable 7-lead ECG patch with companion SmartNeuralNet cloud SaaS platform for continuous 7/14-day cardiac and remote patient monitoring. Provides real-time full-disclosure ECG transmission, AI-driven arrhythmia detection, and clinical reporting for hospitals, cardiologists, and electrophysiologists. Single patch serves MCT, Holter, Extended Holter, and Event Monitoring services.
  • US Cardiac Diagnostic Monitoring Services (IDTF) Outsourced cardiac diagnostic monitoring services (MCT, Holter, Extended Holter, Event Monitoring) delivered through SmartCardia Inc., a wholly-owned US subsidiary operating as a CMS-enrolled IDTF with Joint Commission accreditation. Billed through in-network coverage with major US insurance providers.

Quantifiable outcome

  • False alarms significantly reduced: 5 vs 21 (CCMS) in SMART-TEL clinical study (P = .002)
  • +3 more outcomes

Companies that use SmartCardia

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles2 records

SmartCardia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature5 records

SmartCardia partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cardiomedix, Inc. (acquired and renamed SmartCardia, Inc.)coreStrategic or Co-development Partner · 18 December 2024SmartCardia completed acquisition of Cardiomedix, Inc., a US Independent Diagnostic Testing Facility (IDTF). The acquisition closes the loop on SmartCardia's US offering, combining its FDA-cleared 7-Lead ECG Patch and AI-driven cloud platform with an accredited US diagnostic facility. Cardiomedix operates under SmartCardia brand as wholly-owned US subsidiary with CMS IDTF enrollment and Joint Commission accreditation, enabling end-to-end cardiac monitoring services in the US market.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

SmartCardia competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic is a global cardiac device leader with LINQ implantable loop recorders and broader cardiac diagnostics portfolio. Competes at the high-acuity end of cardiac monitoring and adjacent to SmartCardia's patch-based Holter/MCT offerings.
  • GE HealthCare: GE HealthCare provides hospital telemetry systems, ECG carts, and patient monitoring infrastructure. Competes with SmartCardia in the inpatient telemetry use case and increasingly in wireless/remote monitoring through MUSE and other digital tools.
  • BioTelemetry (Philips): Philips acquired BioTelemetry in 2021, one of the largest US remote cardiac monitoring service providers (MCOT, Holter, Event). Competes with SmartCardia's IDTF channel and offers a broader portfolio including hospital telemetry and sleep diagnostics.

Direct peers

  • iRhythm Technologies: iRhythm's Zio is the market-leading wearable ECG patch for ambulatory cardiac monitoring. Direct competitor in 14-day continuous ECG monitoring with AI-driven arrhythmia detection, serving the same cardiology and hospital customer base.
  • AliveCor: AliveCor's KardiaMobile and KardiaCloud offer consumer-and-professional ECG monitoring with AI-driven arrhythmia detection. Overlaps with SmartCardia in ECG signal capture and cloud-based analysis, though more skewed toward consumer/ambulatory use cases.
  • Preventice Solutions (Boston Scientific): Boston Scientific acquired Preventice (BodyGuardian) in 2022, a direct competitor offering remote cardiac monitoring patches and services (MCT, Event, Holter). Competes head-to-head with SmartCardia in hospital and IDTF channels.
  • VitalConnect: VitalConnect provides wearable biosensor patches (Vista) for continuous vital sign and cardiac monitoring in both hospital and remote patient monitoring settings. Direct competitor in patch-based multi-vital monitoring with cloud analytics.
  • Bardy Diagnostics (Baxter): Baxter acquired Bardy Diagnostics (CAM patch), a single-lead ECG patch focused on ambulatory monitoring. Competes in the same cardiac monitoring patch category with comparable workflow and reimbursement models.

Emerging players

  • Heartbeam: Heartbeam is a smaller public competitor developing 3D ECG signal capture technology for ambulatory cardiac monitoring with AI-driven analysis. Comparable in targeting outpatient telemetry with a differentiated hardware platform.
  • Eko Health: Eko offers AI-powered digital stethoscopes and ECG sensing with cloud analytics. Comparable in cloud-based cardiac AI interpretation and clinician workflow, though primarily device-form-factor different.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

SmartCardia social profiles

Digital presence

SmartCardia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SmartCardia leadership team

Management profile

Number of profiles

Profiles9 records

SmartCardia subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SmartCardia funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SmartCardia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SmartCardia

What does SmartCardia do?

SmartCardia manufactures a 7-lead wireless ECG patch and operates a cloud-based SaaS platform (SmartNeuralNet) for AI-powered cardiac arrhythmia detection and remote patient monitoring. The patch is cable-free, waterproof, and supports 7/14 days of continuous monitoring, transmitting 100% of ECG data and vitals (respiration, SpO2, activity) to the cloud in near real time. In the US, the company also operates an accredited Independent Diagnostic Testing Facility (IDTF) to deliver end-to-end cardiac monitoring services.

Is SmartCardia a public or private company?

SmartCardia is a private company. It is classified as venture growth investor backed and is currently operating.

When was SmartCardia founded?

SmartCardia was founded in 2015. It employs 51 to 100 people.

Where is SmartCardia based?

SmartCardia is headquartered in Lausanne, Switzerland, in the Europe region.

How does SmartCardia make money?

Three revenue lines are on record. Medical Device Hardware Sales are the primary driver. The others are cloud SaaS Platform and diagnostic Services (US).

Who are SmartCardia's main competitors?

Broad incumbents on record are Medtronic, GE HealthCare and BioTelemetry (Philips). Direct peers are iRhythm Technologies, AliveCor, Preventice Solutions (Boston Scientific), VitalConnect and Bardy Diagnostics (Baxter). Emerging players are Heartbeam and Eko Health.

Does SmartCardia have an API?

No public API is recorded for SmartCardia.

What industry is SmartCardia in?

SmartCardia's product category is Cardiac Monitoring Devices. Its primary akta.pro industry code is HLAHACAB, Cardiac Monitoring (ECG/Holter/Event/Patch, Loop Recorders), with a secondary code of HLALAGAB, Cardiology Telemedicine Platforms. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Knowledge Sourcing IntelligencePortable Medical Devices Market Insights: Share, Forecast 2030A market research report projects the global portable medical devices market will grow from $56.50 billion in 2025 to $87.10 billion by 2030, representing a compound annual growth rate of 9.1%. Key growth drivers include rising chronic diseases, expanding elderly populations, technological advancements in wearable and wireless medical devices, and increasing preference for home healthcare settings. The report profiles multiple companies actively launching products in this space, including Samsung, GE Healthcare, Medtronic, Clarius Mobile Health, Max Ventilator, Mobvoi, Biocorp, Novo Nordisk, and SmartCardia.PR NewswireSmartCardia Strengthens U.S. Board With Addition of Veteran Cardiac Device Leader Ken NelsonSmartCardia, a Swiss cardiac monitoring company that recently received FDA clearance for its 7-lead real-time ECG monitoring patch and cloud platform, announced the addition of Ken Nelson to its U.S. Board of Directors to advise on commercialization and overall strategy. Nelson brings extensive experience in cardiac digital health, having built commercial teams and launched patch monitoring products at iRhythm, BioTelemetry, and Bardy Diagnostics. The appointment supports SmartCardia's global expansion plans, as the company has already launched its AI-enabled ECG monitoring system commercially in several European countries and India.startupticker.chGlobal accelerators propel Swiss life sciencesThree Swiss life sciences startups—MPC Therapeutics, SmartCardia, and ONWARD—have secured positions in major global accelerator programs in the US and Germany, gaining access to investment capital and clinical networks. MPC Therapeutics joined Johnson & Johnson’s JLABS ecosystem, while SmartCardia entered the HeartX Accelerator with a $150,000 investment, and ONWARD received recognition from Germany’s Techniker Krankenkasse. These moves provide the companies with critical resources for product development, pilot projects, and strategic partnerships.PR NewswireSmartCardia Receives FDA Clearance for its 14-Day 7-Lead ECG Real-Time Patch and Cloud PlatformSmartCardia, a medical device company based in Lausanne, Switzerland, has received FDA clearance for its 7-lead real-time ECG monitoring patch and cloud platform, which is waterproof, cable-free, and capable of continuous monitoring for up to 14 days. The platform transmits 100% of ECG data in real-time, features automated arrhythmia detection, visual and audio alarms, and clinician notifications. The company, which already has CE Class IIa approval and widespread adoption in Europe and India, plans to expand into the US market following this regulatory clearance.PR NewswireSmartCardia Earns Frost & Sullivan's 2022 Global New Product Innovation Award in the Cardiac-monitoring Wearables IndustryFrost & Sullivan has awarded SmartCardia its 2022 Global New Product Innovation Award for the company's 7-lead ECG monitoring patch that records and transmits vital signs in real time with AI-based cloud analytics. The patch monitors ECG, heart rate, respiration rate, oxygen saturation, and activity simultaneously, offering clinical-quality data to healthcare practitioners. SmartCardia, which currently operates globally, has announced plans to enter the US market in 2023.PR NewswireSmartCardia Earns Frost & Sullivan's 2022 Global New Product Innovation Award in the Cardiac-monitoring Wearables IndustryFrost & Sullivan awarded SmartCardia its 2022 Global New Product Innovation Award for the company's multiparameter cardiac monitoring patch that records 7-lead ECG, heart rate, respiration rate, oxygen saturation, and activity data in real time using AI-based cloud analytics. The patch detects 20 different arrhythmias and enables continuous patient monitoring without additional devices, delivering clinical-quality data to healthcare practitioners. SmartCardia plans to enter the US market in 2023 as part of its strategy to expand its global presence.FrontiersCardiac Ambulatory Monitoring: New Wireless Device Validated Against Conventional Holter Monitoring in a Case SeriesA trial of 40 patients compared the SmartCardia wireless patch to a 24-hour Holter monitor for arrhythmia detection. No significant difference was found in detecting ventricular and supraventricular arrhythmias, pauses, or AVB. The authors suggest the patch could be an alternative to conventional Holter monitoring.